Teduglutide, a novel mucosally active analog of glucagon-like peptide-2 (GLP-2) for the treatment of moderate to severe Crohn's disease

Inflammatory Bowel Diseases

Volumn 16, Issue 6, 2010, Pages 962-973

  Buchman, Alan L ^a   Katz, Seymour ^b   Fang, John C ^c   Bernstein, Charles N ^d   Abou Assi, Souheil G ^e  

^a NORTHWESTERN UNIVERSITY   (United States)

^b LONG ISLAND JEWISH MEDICAL CENTER   (United States)

^c UNIVERSITY OF UTAH   (United States)

^d UNIVERSITY OF MANITOBA   (Canada)

^e VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Citrullene; Crohn's disease; Glucagon like peptide II; Teduglutide; Treatment

Indexed keywords

CITRULLINE; INFLIXIMAB; PLACEBO; TEDUGLUTIDE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; TREATMENT OUTCOME;

ADOLESCENT; ADULT; CITRULLINE; CROHN DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GASTROINTESTINAL AGENTS; GLUCAGON-LIKE PEPTIDE 2; HUMANS; MALE; MIDDLE AGED; PEPTIDES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77952679996     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21117     Document Type: Article

References (76)

1. Lichtenstein GR, Yan S, Bala M, et al. Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries. Am J Gastroenterol. 2004;99:91-96. (Pubitemid 38679108)
2. Munkholm P, Langholz E, Davidsen M, et al. Intestinal cancer risk and mortality in patients with Crohn's disease. Gastroenterology. 1993;105:1716-1723. (Pubitemid 24002788)
3. Sonnenberg A. Disability from inflammatory bowel disease among employees in West Germany. Gut. 1989;30:367-370. (Pubitemid 19091164)
4. Feagan BG, Bala M, Yan S, et al. Unemployment and disability in patients with moderately to severely active Crohn's disease. J Clin Gastroenterol. 2005;39:390-395. (Pubitemid 40548076)
5. Loftus EV Jr. Crohn's disease: why the disparity in mortality? Gut. 2006;55:4429.
6. Wolters FL. Crohn's disease: increased mortality 10 years after diagnosis in a Europe-wide population based cohort. Gut. 2006;55: 510-518.
7. Hollander D, Vadheim CM, Brettholz E, et al. Increased intestinal permeability in patients with Crohn's disease and their relatives: a possible etiological factor? Ann Intern Med. 1986;105:883-885.
8. Sandborn WJ, Colombel JF, Enns R, et al. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med. 2005;353: 1912-1925. (Pubitemid 41565956)
9. Hanauer SB, Sandborn WJ, Rutheerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-1 trial. Gastroenterology. 2006;130:323-333.
10. Targan SR, Feagan B, Fedorak R, et al. Natalizumab for the treatment of active Crohn's disease: results from the ENCORE trial. Gastroenterology. 2007;132:1672-1683. (Pubitemid 46695722)
11. Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med. 2007;357:228-238. (Pubitemid 47080387)
12. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's disease cA2 study group. N Engl J Med. 1997;337:1029-1035.
13. Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med. 2007;357:228-238. (Pubitemid 47080387)
14. Papadakis KA, Targan SR. Tumor necrosis factor biology and therapeutic inhibitors. Gastroenterology. 2000;119:1148-1157.
15. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. N Engl J Med. 1997;337:1029-1035.
16. Guan X, Karpen HE, Stephens J, et al. GLP-2 receptor localizes to enteric neurons and endocrine cells expressing vasoactive peptides and mediates increased blood flow. Gastroenterology. 2006;130:150-164. (Pubitemid 43049845)
17. Orskov C, Hartmann B, Poulsen SS, et al. GLP-2 stimulates colonic growth via KGF, released by subepithelial myofibroblasts with GLP-2 receptors. Regul Pept. 2005;124:105-112. (Pubitemid 39488347)
18. Yusta, Huang L, Munroe D, et al. Enteroendocrine localization of GLP-2 receptor expression in humans and rodents. Gastroenterology. 2000;119:744-745.
19. Munroe DG, Gupta AK, Kooshesh F, et al. Prototypic G protein-coupled receptor for the intestinotrophic factor glucagon-like peptide 2. Proc Natl Acad Sci USA. 1999;96:1569-1573. (Pubitemid 29098492)
20. Nelson DW, Sharp JW, Brownfield MS, et al. Localization and activation of GLP-2 receptors on vagal afferents in the rat. Endocrinology. 2007;148:1954-1962.
21. Bjerknes M, Cheng H. Modulation of specific intestinal epithelial progenitors by enteric neurons. Proc Natl Acad Sci USA. 2001;98:12497-12502. (Pubitemid 33019974)
22. Wallace LE, Martin G, Swain MG, et al. Acute GLP-2 treatment induces effects in both peripheral and central nervous systems (abstract). Can J Gastroenterol. 2004;18:A120.
23. Rocha FG, Shen KR, Jasleen J, et al. Glucagon-like peptide 2: divergent signaling pathways. J Surg Res. 2004;121:5-12. (Pubitemid 39094089)
24. Walsh NA, Yusta B, DaCambra MP, et al. Glucagon-like peptide-2 receptor activation in the rat intestinal mucosa. Endocrinology. 2003;144:4385-4392. (Pubitemid 37204837)
25. Yusta B, Huang L, Munroe D, et al. Enteroendocrine localization of GLP-2 receptor expression in humans and rodents. Gastroenterology. 2000;119:744-755.
26. Sigalet DL, Bawazir O, Martin GR, et al. Glucagon-like peptide-2 induces a specific pattern of adaptation in remnant jejunum. Dig Dis Sci. 2006;51:1557-1566. (Pubitemid 44379297)
27. Xiao Q, Boushey RP, Cino M, et al. Circulating levels of glucagon-like peptide-2 in human subjects with inflammatory bowel disease. Am J Physiol Regul Integr Comp Physiol. 2000;278:R1057-1063.
28. Schmidt PT, Hartmann B, Bregenholt S, et al. Deficiency of the intestinal growth factor, glucagon-like peptide 2, in the colon of SCID mice with inflammatory bowel disease induced by transplantation of CD4+ T cells. Scand J Gastroenterol. 2000;35:522-527. (Pubitemid 30354093)
29. Ivory C,Wallace LE, de Heuvel E, et al. Glucagon-like peptide-2 improves healing of TNBS colitis by altering immune regulatory cell signalling in the lamina propia (abstract). Gastroenterology. 2008;A-506.
30. Drucker DJ, Shi Q, Crivici A, et al. Regulation of the biological activity of glucagon-like peptide 2 in vivo by dipeptidyl peptidase IV. Nat Biotechnol. 1997;15:673-677. (Pubitemid 27291170)
31. Martin GR, Wallace LE, Hartmann B, et al. Nutrient-stimulated GLP-2 release and crypt cell proliferation in experimental short bowel syndrome. Am J Physiol Gastrointest Liver Physiol. 2005;288:G431-438.
32. Burrin DG, Stoll B, Guan X, et al. Glucagon-like peptide 2 dose-dependently activates intestinal cell survival and proliferation in neonatal piglets. Endocrinology. 2005;146:22-32. (Pubitemid 40051718)
33. Shin ED, Estall JL, Izzo A, et al. Mucosal adaptation to enteral nutrients is dependent on the physiologic actions of glucagon-like peptide-2 in mice. Gastroenterology. 2005;128:1340-1353. (Pubitemid 40712184)
34. Burrin DG, Stoll B, Jiang R, et al. GLP-2 stimulates intestinal growth in premature TPN-fed pigs by suppressing proteolysis and apotosis. Am J Physiol. 2000;279:G1249-G1256.
35. Kouris GJ, Liu Q, Rossi H, et al. The effect of glucagon-like peptide 2 on intestinal permeability and bacterial translocation in acute necrotizing pancreatitis. Am J Surg. 2001;181:571-575. (Pubitemid 32769988)
36. Cottrell JJ, Stoll B, Buddington RK, et al. Glucagon-like peptide-2 protects against TPN-induced intestinal hexose malabsorption in enterally refed piglets. Am J Physiol Gastrointest Liver Physiol. 2006;290:G293-G300.
37. Brubaker PL, Izzo A, Hill M, Drucker DJ. Intestinal function in mice with small bowel growth induced by glucagon-like peptide-2. Am J Physiol. 1997;272:E1050-E1058. (Pubitemid 27293147)
38. Jeppesen PB, Hartmann B, Thulesen J, et al. Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short bowel patients with no colon. Gastroenterology. 2001;120:806-815. (Pubitemid 32193176)
39. Jeppesen PB, Sanguinetti EL, Buchman AL, et al. Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients. Gut. 2005;54:1224-1231.
40. O'Keefe SJ, Gilroy R, Jeppessen PB, et al. Teduglutide, a novel GLP-2 analog, in the management of short bowel syndrome (SBS) patients dependent on parenteral nutrition: a multicenter multinational placebo-controlled clinical trial. Gastroenterology. 2008;134:27A.
41. Benjamin MA, McKay DM, Yang PC, et al. Glucagon-like peptide-2 enhances intestinal epithelial barrier function of both transcellular and paracellular pathways. Gut. 2000;47:112-119.
42. L'Heureux MC, Brubaker PL. Glucagon-like peptide-2 and common therapeutics in a murine model of ulcerative colitis. J Pharmacol Exp Ther. 2003;306:347-354.
43. Drucker DJ, Yusta B, Boushey RP, et al. Human [Gly2]GLP-2 reduces the severity of colonic injury in a murine model of experimental colitis. Am J Physiol. 1999;276:G79-G91. (Pubitemid 29063603)
44. Alavi K, Schwartz MZ, Palazzo JP, et al. Treatment of inflammatory bowel disease in a rodent model with the intestinal growth factor glucagon-like peptide-2. J Pediatr Surg. 2000;35:847-851. (Pubitemid 30346176)
45. Arthur GL, Schwartz MZ, Kuenzler KA, et al. Glucagonlike peptide-2 nalogue: a possible new approach in the management of inflammatory bowel disease. J Pediatri Surg. 2004;39:448-452.
46. Boushey RP, Yusta B, Drucker DJ. Glucagon-like peptide 2 decreases mortality and reduces the severity of indomethacin-induced murine enteritis. Am J Physiol. 1999;277:E937-E947.
47. Cameron H, Yang PC, Perdue MH. Glucagon-like peptide-2-enhanced barrier function reduces pathophysiology in a model of food allergy. Am J Physiol Gastrointest Liver Physiol. 2003;284:G905-G912. (Pubitemid 36597332)
48. Best WR, Becktel M, Singleton JW. Rederived values of the eight coefficients of the Crohn's Disease Activity Index (CDAI). Gastroenterology. 1979;77:843-846.
49. Crenn P, Vahedi K, Lavergne-Slove A, et al. Plasma citrulline: a marker of enterocyte mass in villous atrophy-associated small bowel disease. Gastroenterology. 2003;124:1210-1219. (Pubitemid 36531797)
50. Crenn P, Coudray-Lucas C, Thuillier F, et al. Postabsorptive plasma citrulline concentration is a marker of absorptive enterocyte mass and intestinal failure in humans. Gastroenterology. 2000;119:1496-1505. (Pubitemid 32198675)
51. Lutgens LCHW, Deutz N, Granzier-Peeters M, et al. Plasma citrulline concentration: a surrogate end point for radiation-induced mucosal atrophy of the small bowel. A feasibility study in 23 patients. Int J Radiat Onc Biol Phys. 2004;60:275-285. (Pubitemid 39165495)
52. Gondolesi G, Ghirardo S, Raymond K, et al. The value of plasma citrulline to predict mucosal injury in intestinal allografts. Am J Transplant. 2006;6:2786-2790. (Pubitemid 44571701)
53. Blijievens NM, Lutgens LC, Schattenberg AV, et al. Citrulline: a potentially simple quantitative marker of intestinal epithelial damage following myeloblative therapy. Bone Marrow Transplant. 2004;34:193-196.
54. David AI, Selvaggi G, Ruiz P, et al. Blood citrulline is an exclusionary marker for significant acute rejection after intestinal transplantation. Transplantation. 2007;84:1077-1081. (Pubitemid 350125347)
55. Papadia C, Sherwood RA, Kalantzis C, et al. Plasma citrulline concentration: a reliable marker of small bowel absorptive capacity independent of intestinal inflammation. Am J Gastroenterology. 2007;102:1474-1482. (Pubitemid 46976295)
56. Su C, Lichtenstein GR, Krok K, et al. A meta-analysis of the placebo rates of remission and response in clinical trials of active Crohn's disease. Gastroenterology. 2004;126:1257-1269. (Pubitemid 38552790)
57. Sinha A, Nightingale J, West KP, et al. Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis. N Engl J Med. 2003;349:350-357. (Pubitemid 36886241)
58. Schreiber S, Rutgeerts P, Fedorak RN, et al. A randomized, placebo-controlled trial of certolizumab pego (CDP870) for treatment of Crohn's disease. Gastroenterology. 2005;129:807-818. (Pubitemid 41242673)
59. De Dombal FT, Softley A. IOBID report no 1. Observer variation in calculating indices of severity and activity in Crohn's disease. International Organization for the Study of Inflammatory Bowel Disease. Gut. 1987;28:474-481.
60. Thompson WG. Gastrointestinal symptoms in the irritable bowel compared with peptic ulcer and inflammatory bowel disease. Gut. 1984;25:1089-1092. (Pubitemid 14002124)
61. Simren M, Axelsson J, Gillberg R, et al. Quality of life in inflammatory bowel disease in remission: the impace of IBD-like symptoms and associated psychological factors. Am J Gastroenterol. 2002;97:389-396. (Pubitemid 34160766)
62. Minderhoud IM, Oldenburg B, Wismeijer JA, et al. IBD-like symptoms in patients with inflammatory bowel disease in remission; relationships with quality of life and coping behavior. Dig Dis Sci. 2004;49:469-474. (Pubitemid 38453568)
63. Barratt HS, Kalantzis C, Polymeros D, et al. Functional symptoms in inflammatory bowel disease and their potential influence in misclassification of clinical status. Aliment Pharmacol Ther. 2005;21:141-147. (Pubitemid 40222966)
64. Farrokhyar F, Marshall JK, Easterbrook B, et al. Functional gastrointestinal disorders and mood disorders in patients with inactive inflammatory bowel disease: prevalence and impact on health. Inflamm Bowel Dis. 2006;12:38-46. (Pubitemid 43032450)
65. Slonim AE, Bulone L, Damore MB, et al. A preliminary study of growth hormone therapy for Crohn's disease. N Engl J Med. 2000;342:1633-1637.
66. Stephens J, Stoll B, Cottrell J, et al. Glucagon-like peptide-2 acutely increases proximal small intestinal blood flow in TPN-fed neonatal piglets. Am J Physiol Regul Integr Physiol. 2006;290:R283-289.
67. Bremholm L, Hornum M, Henriksen BM, et al. Glucagon-like peptide-2 increases mesenteric blood flow in humans. Scand J Gastroenterol. 2009;44:314-319.
68. Bulut K, Meier JJ, Ansorge N, et al. Glucagon-like peptide 2 improves intestinal wound healing through induction of epithelial cell migration in vitro-evidence for a TGF-beta-mediated effect. Regul Pept. 2004;121:137-143.
69. Deniz M, Bozkurt A, Kurtel H. Mediators of glucagon-like peptide 2-induced blood flow: responses in different vascular sites. Regul Pept. 2007;142:7-15.
70. Thulesen J, Hartmann B, Hare KJ, et al. Glucagon-like peptide 2 (GLP-2) accelerate the growth of colonic neoplasms in mice. Gut. 2004;53:1145-1150.
71. Chance WT, Sheriff S, Foley-Nelson T, et al. Maintaining gut integrity during parenteral nutrition of tumor-bearing rats: effects of glucagon-like peptide 2. Nutr Cancer. 2000;37:215-222.
72. Jeppesen PB, Gottschlack I, Mortensen PB. Long-term treatment with glucagon-like peptide 2 (GLP-2) in patients with short bowel syndrome, compliance, safety, and effects on dietary intake and absorption evaluated in a 52 week study. Gastroenterology. 2005;128:A57.
73. Jeppesen PB, Gottschalck IB, Holst JJ, et al. Improvements in renal function in short bowel syndrome (SBS) patients treated for two years with subcutaneous native glucagon-like peptide 2 (GLP-2) (abstract). Gastroenterology. 2008;134:A427.
74. Caddy G, Johnston C, Ardill J, et al. Distribution of glucagon-like peptide-2 in normal colonic tissue. Scand J Gastroenterol. 2003;38:798-799.
75. Litvak DA, Hellmich MR, Evers BM, et al. Glucagon-like peptide 2 is a potent growth factor for small intestine and colon. J Gastrointest Surg. 1998;2:146-150.
76. Schmidt PT, Ljung T, Hartmann B, et al. Tissue levels and post-prandial secretion of the intestinal growth factor, glucagon-like peptide-2, in controls and inflammatory bowel disease: comparison with peptide YY. Eur J Gastroenterol Hepatol. 2005;17:207-212.